FDA Approves an Anti-Amyloid for Alzheimer's disease

Lecanemab , an anti-amyloid beta protofibril antibody, was approved under the FDA's accelerated approval pathway. This treatment option is the latest therapy to target and affect the underlying disease process of Alzheimer's instead of treating the symptoms.

The FDA approved this treatment on the basis of a clinical trail which showed cognitive benefit for patients with early Alzheimer's disease. But it seems that it can raise the possibility of cerebral hemorrhages. Other clinical trials have to be processed to fully measure the benefits and the adverse events.

Alvaro Pascual-Leone, MD, PhD, professor of neurology said the it is a very exciting development and prospect but [...] some critical issues need to be considered. The likely more promising approach is the addition of other therapies to Lecanemab as part of multi-intervention strategy: pharmacologic and nonpharmacologic interventions.

Source : FDA approves second anti-amyloid for Alzheimer's disease, Megan Brooks, www.medscape.com